Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr 15;47(5):607-14.
doi: 10.1097/QAI.0b013e3181648e16.

Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children

Katherine Tassiopoulos  1 , Paige L Williams, George R Seage 3rd, Marilyn Crain, James Oleske, John Farley; International Maternal Pediatric Adolescent AIDS Clinical Trials 219C Team
Collaborators, Affiliations

Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children

Katherine Tassiopoulos et al. J Acquir Immune Defic Syndr. .

Abstract

Context: Antiretroviral therapy has been associated with hypercholesterolemia in HIV-infected children. Few longitudinal studies have been conducted to examine this association, however.

Objective: To evaluate the incidence of and risk factors for development of hypercholesterolemia in a large pediatric study.

Design: Prospective cohort study (Pediatric AIDS Clinical Trials Group 219C).

Participants: A total of 2122 perinatally HIV-infected children free of hypercholesterolemia at entry.

Outcome: Development of hypercholesterolemia (total cholesterol >or=220 mg/dL at 2 consecutive visits). Cox proportional hazards models were used to evaluate risk factors.

Results: Thirteen percent of children had hypercholesterolemia at entry, and an additional 13% developed hypercholesterolemia during follow-up for an incidence rate of 3.4 cases per 100 person-years (95% confidence interval [CI]: 3.0 to 3.9). After adjustment for age, boosted protease inhibitor (PI) use (hazard ratio [HR] = 13.9, 95% CI: 6.73 to 28.6), nonboosted PI use (HR = 8.65, 95% CI: 4.19 to 17.9), and nonnucleoside reverse transcriptase inhibitor use (HR = 1.33, 95% CI: 1.04 to 1.71) were associated with increased risk of hypercholesterolemia, and higher viral load was protective (>50,000 vs. <or=400 copies/mL; HR = 0.59, 95% CI: 0.39 to 0.90). Self-reported adherent subjects had higher risk.

Conclusions: PIs were significant risk factors for hypercholesterolemia. Higher viral load was protective and may reflect nonadherence. Further follow-up is critical to evaluate long-term consequences of chronic PI exposure and hypercholesterolemia.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Estimated probability of remaining free of hypercholesterolemia, by baseline HAART regimen.
See this image and copyright information in PMC

References

    1. Gortmaker S, Hughes M, Cervia J, et al. for the Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522–1528. - PubMed
    1. Gona P, Van Dyke R, Williams P, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAARTera. JAMA. 2006;296:292–300. - PubMed
    1. Storm D, Boland M, Gortmaker S, et al. for the Pediatric AIDS Clinical Trials Group Protocol 219 Study Team. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection. Pediatrics. 2005;115:e173–e182. - PubMed
    1. Lee G, Gortmaker S, McIntosh K, et al. for the Pediatric AIDS Clinical Trials Group Protocol 219C Team. Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment. Pediatrics. 2006;117:273–283. - PubMed
    1. Buchacz K, Rogol A, Lindsey J, et al. for the Pediatric AIDS Clinical Trials Group 219 Study Team. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. J Acquir Immune Defic Syndr. 2003;33:56–65. - PubMed

Publication types

MeSH terms